S&P Futures
4,363.75 -15.00 (-0.34%) Dow Futures
34,165.00 -108.00 (-0.32%) Nasdaq Futures
14,882.50 -52.75 (-0.35%) Russell 2000 Futures
1,793.10 -7.80 (-0.43%) Crude Oil
88.82 -0.86 (-0.96%) Gold
1,931.00 -5.60 (-0.29%)
Molecular Partners AG (6ML0.DU)
Chart Events
Performance Outlook
| Previous Close | 3.8200 |
| Open | 4.2400 |
| Bid | 4.0600 x N/A |
| Ask | 4.4600 x N/A |
| Day's Range | 4.0000 - 4.0000 |
| 52 Week Range | 3.8200 - 6.9500 |
| Volume | |
| Avg. Volume | 6 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for 6ML0.DU
Related Research
GlobeNewswireMolecular Partners Presents New Data on its Radio DARPin Therapy (RDT) Platform at the EANM 2023 Annual Meeting
New preclinical RDT data show that DARPins can be engineered to increase tumor uptake as well as reducing accumulation in kidneys Engineering solutions transferrable across the platform and to a broad range of tumor targets RDT platform offers unique approach for tailored delivery of radioactive payloads to solid tumors and for expansion of targets amenable to radiotherapy ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDA
- GlobeNewswire
Molecular Partners Reports H1 2023 Corporate Highlights and Financials
Phase 1/2a clinical trial of tetraspecific T cell engager candidate MP0533 initiated in patients with relapsed/refractory AML and MDS/AML; dosing ongoing in the 4th dose cohort; initial data expected in Q4 2023 Positive MP0317 data of ongoing Phase 1 clinical trial presented at ASCO confirm proposed MOA and indicates favorable safety profile in patients with advanced solid tumors, supporting future combination studies with potential partners; presently finalizing recruitment of weekly dosing reg
- GlobeNewswire
Molecular Partners to Present on its Radio DARPin Therapy (RDT) Platform at SNMMI 2023
RDT platform offers unique approach for tailored delivery of radioactive payloads to solid tumors RDT platform is focused on improving both tumor-targeting efficiency and safety over historic protein-based radioligand approaches ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 27, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, has announced it will
